Zhongxin Jingwei, January 19 -- On January 18, the National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Catalogue (2022) was announced. Hengrui Pharmaceutical's many blockbuster innovative drugs and first generic products were included in the new version of the catalog. Dalcilli isethionate tablets (trade name: Arlikon), proline hengliflozin tablets (trade name: Ruiqin), revilumide tablets (trade name: Irion ®) 3 innovative drugs, ondansetron ® oral dissolving film (trade name: Aiqisu), ® pregabalin ® sustained-release tablets (trade name: Rebecare ®) were included in the catalog for the first time through negotiation; One new indication of innovative drug remazolam tosylate (trade name: rembinin ®) for injection was included in the catalogue through negotiation; The 4 new indications of carrelizumab (trade name: Erica ®) for PD-1 inhibitor injection and esketamine hydrochloride injection (brand name: Es) ® have completed the indication access and renewal through the new "simple renewal" regulations, benefiting patients at a more favorable price; Peaspartase injection (trade name: Ai Yang ®) is included in the routine catalog management.
So far, Hengrui Pharmaceutical's products have entered the national medical insurance drug catalogue in total, of which all 11 innovative drugs listed by the company have entered medical insurance, further improving the accessibility and affordability of drugs for patients.
The three newly launched innovative drugs were all negotiated into medical insurance
In 2022, Hengrui Pharma has 3 self-developed innovative drugs approved for marketing, namely Dalcilli isethionate tablets (trade name: Arlikon), proline hengliflozin tablets (trade name: Ruiqin ®) and revilumide tablets (brand name: Arion ® ®), all of which were included in the national medical insurance drug catalogue through this medical insurance negotiation.
Dalcilib isethionate tablets (trade name: Arlikon ®) is the first self-developed new highly selective CDK4/6 inhibitor in China, combined with fulvestrant, for the treatment of recurrent or metastatic breast cancer that progresses after endocrine therapy with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative. The launch of Dalcili has strongly promoted the application of CDK4/6 inhibitors and brought new treatment options to breast cancer patients in China.
Proline hengliflozin tablets (trade name: Ruiqin ®) is the first self-developed SGLT2 inhibitor in China to improve blood glucose control in adults with type 2 diabetes. In recent years, Hengrui Pharmaceutical has made an extensive R&D pipeline layout in the field of diabetes, and proline hengliflozin tablets are still developing compound preparations with metformin and DPP4 inhibitors, and are committed to providing more diversified options for clinical applications.
Revilumide tablets (trade name: Irene ®) is the first self-developed novel androgen receptor (AR) inhibitor in China for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) patients with high tumor burden. As a new second-generation AR inhibitor, revilumide has made important innovations in the molecular structure of drugs, bringing more clinical benefits to patients. Revilumide has been recommended by the Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Prostate Cancer (2022 Edition) (Class 1A evidence).
In addition, a new indication of the innovative drug remazolam tosylate for injection (trade name: rembinin ®), which was previously included in the national medical insurance drug list, was also included through negotiation this time.
Four new indications for carrelizumab were included through "simple renewal"
"Easy renewal" is a new rule for health care negotiations this year. Under this new rule, Hengrui Pharmaceutical's two products that have previously been included in the national medical insurance drug catalogue were renewed, further benefiting more patients at preferential prices.
Since the last inclusion of PD-1 inhibitor carrelizumab for injection (trade name: Erica ®), 4 new indications have been added since the last medical insurance, covering the first-line treatment of squamous non-small cell lung cancer, esophageal cancer, nasopharyngeal carcinoma, and this time they are included in the new version of the catalog through "simple renewal".
Carrelizumab is a humanized PD-1 monoclonal antibody independently developed by Hengrui Pharmaceutical and has intellectual property rights. Since its approval for marketing in May 2019, it has been approved for 8 indications in the five major tumor types of lung cancer, liver cancer, esophageal cancer, nasopharyngeal cancer and lymphoma, and is the leading domestic PD-1 product with the approved indication and the number of tumor types covered. Through this simple renewal, all 8 approved indications of carrelizumab are included in medical insurance, further expanding the patient population that can be served.
At the same time, the company's surgical drug product esketamine hydrochloride injection (trade name: ace ®) has also been simply renewed and continues to serve the majority of patients in the new version of the catalog.
A domestic first generic product to benefit patients in medical insurance
In addition, Hengrui Pharmaceutical also has the first domestic generic product to be included in the catalog for the first time through medical insurance negotiations. Ondansetron oral film (trade name: Aiqisu), ® suitable for the prevention of nausea and vomiting caused by hyperemetogenic chemotherapy, the prevention of nausea and vomiting caused by moderate emetogenic chemotherapy, the prevention of nausea and vomiting caused by radiotherapy, and the prevention of nausea and/or vomiting after surgery. The company's ondansetron oral dissolving film is the first imitation listed in China. Oral dissolving membrane is a new drug delivery system, which has the characteristics of fast dissolution, convenient administration and high patient compliance compared with traditional oral preparations, especially suitable for the elderly, children with dysphagia and special patients with poor compliance.
Another product, pregabalin sustained-release tablets (trade name: Rebecare ®), has also been added for the treatment of postherpetic neuralgia. Unlike the marketed pregabalin capsules taken 2 or 3 times a day, pregabalin sustained-release tablets, as the first self-developed sustained-release dosage form in China, only need to be taken once a day after dinner, which helps improve patients' medication compliance.
Actively supporting medical insurance to benefit the people, Hengrui is committed to protecting public health with pharmaceutical innovation
As an innovative international pharmaceutical enterprise, Hengrui Pharmaceutical has long practiced the mission of "science and technology-oriented, creating a healthy life for mankind", always adhered to the original intention of serving patients, and focused on unmet clinical needs to carry out innovative research and development. In recent years, with the reform and improvement of the national medical security system and policies, Hengrui Pharmaceutical has actively supported the national medical insurance initiative to benefit the people, fulfilled its corporate social responsibility, and continuously improved the accessibility and affordability of high-quality drugs used by patients.
According to statistics, after the release of the new version of the medical insurance drug catalog, Hengrui Pharmaceutical has accumulated 93 products included in the national medical insurance, of which all 11 innovative drugs that have been listed have been included, continuously improving the quality and efficiency of pharmaceutical innovation achievements benefiting people's livelihood.
At present, Hengrui Pharmaceutical has 11 innovative drugs such as revilumide, dalcilide and carrelizumab approved for marketing, the company's introduction of class 1 new drug linplisept has also been approved for marketing, more than 60 innovative drugs are under clinical development, more than 260 clinical trials are carried out at home and abroad, and a number of international leading new technology platforms with independent intellectual property rights have been established to provide a strong foundation for continuous production of innovative results.
The relevant person in charge of Hengrui Pharmaceutical said that in the future, Hengrui Pharmaceutical will continue to uphold the concept of patient-centered, concentrate on pharmaceutical innovation, deepen the health cause, actively support and cooperate with national pharmaceutical policies, strive to improve the accessibility and affordability of patients, and let more domestic new drugs and good drugs better benefit patients. (Zhongxin Jingwei APP)